Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005054 · ClinicalTrials.gov registry record · Phase 2
StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects
A Phase 2 study, sponsored by Stratatech, a Mallinckrodt Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03005054: Clinical Trial Phase 2 study, sponsored by Stratatech, a Mallinckrodt Company.
NCT03005054 is a Phase 2 study that was terminated before completion, run by Stratatech, a Mallinckrodt Company. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03005054, a Phase 2 study, was terminated before completion, sponsored by Stratatech, a Mallinckrodt Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
About 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body. This condition is called full-thickness complex skin defects resulting from acute traumatic skin loss. Participants will be treated with StrataGraft skin tissue to evaluate it's safety and effectiveness for use in treating full-thickness complex skin defects.
Primary Outcome
The percentage of the treatment site area initially covered with StrataGraft tissue that requires autograft by three months will be determined.
Interventions
- BIOLOGICAL StrataGraft Skin Tissue
- PROCEDURE Autograft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 2 |
Why NCT03005054 stopped before completion
NCT03005054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which StrataGraft Skin Tissue is the first listed.
NCT03005054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03005054 about?
NCT03005054 is a clinical study titled "StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects". About 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body. This condition is called full-thickness complex skin defects resulting from acute traumatic skin loss. Particip...
What is the current status of trial NCT03005054?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-04-24. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT03005054?
The interventions under investigation include: StrataGraft Skin Tissue (BIOLOGICAL), Autograft (PROCEDURE).
Who is sponsoring clinical trial NCT03005054?
This trial is sponsored by Stratatech, a Mallinckrodt Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03005054's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI